Skip to main content

Table 2 Tumour response

From: Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

 

Patients, n(%)

Response according to irRC

Aged > 70 years (n = 188)

Aged ≥ 80 years (n = 26)

Aged ≤ 70 years (n = 645)

irCR

4 (2)

0 (0)

25 (4)

irPR

24 (13)

1 (4)

58 (9)

irSD

44 (23)

7 (27)

131 (20)

irPD

116 (62)

18 (69)

431 (67)

irBORR

28 (15)

1 (4)

83 (13)

irDCR

72 (38)

8 (31)

214 (33)

  1. [Note to authors: summarised these data as a table and added data for patients ≥80 years].
  2. irBORR, immune-related best overall response rate; irCR, immune-related complete response; irDCR, immune-related disease control rate; irPD, immune-related progressive disease; irPR, immune-related partial response; irRC, immune-related response criteria; irSD, immune-related stable disease.